[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625116":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":11,"id":43,"slug":11,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"University of Vienna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"STudy group","EXPERIMENTAL",null,[13],"Diagnostic Test: EBUS-TBNA",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","EBUS-TBNA","During EBUS staging, the needle well be changed between all lymph node stations in a first round. The EBUS staging will be repeated without the change of the needle between the lymph node stations.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Daniela Gompelmann","CONTACT","0043 1 40400 47730","daniela.gompelmann@meduniwien.ac.at",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Medical University of Vienna","RECRUITING","Vienna","Austria",{"type":33,"coordinates":34},"Point",[35,36],16.37208,48.20849,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":41,"investigatorFullName":22,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof. Dr. med.","100625116",false,"NCT07418450","Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?","Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study","Inclusion Criteria:\n\n* Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer\n* indication for mediastinal staging\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":52,"type":53},30,"ESTIMATED","INTERVENTIONAL",[56],"NA","During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.",[59],"Lung Cancer (Diagnosis)","2026-02-10",{"date":62,"type":63},"2026-02-18","ACTUAL",{"date":65,"type":63},"2025-11-05",{"date":67,"type":53},"2027-05",{"name":5,"class":6},1]